PROVIDE-HF- Patient Reported Outcomes investigation following Initiation of Drug therapy with Entresto (Sacubitril/Valsartan) in Heart Failure


  • Dr. Marc Simon, Dr. Ravi Ramani, and Dr. Michael Mathier

Purpose: To look at the change in patient-reported HF symptoms via the KCCQ following the initiation of sacubitril/valsartan (continuous measure) through 12-weeks.

Study Design: Prospective Study.

PaTH Partners: Johns Hopkins University, University of Pittsburgh

Sponsor: Novartis

PaTH Network Logo
Twitter Logo Facebook Logo LinkedIn Logo YouTube Logo

Copyright 2016 | PaTH Network